BenevolentAI

News

Pharma's spend on AI in drug discovery 'could top $3bn by 20...

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and developmen

News

AI-based drug discovery firm BenevolentAI cuts SPAC deal

UK artificial intelligence specialist BenevolentAI has said it will float on the Amsterdam Euronext exchange in what is being touted as Europe's largest ever special purpose acquisition com

Views & Analysis

COVID heralds a faster future for drug development (if stake...

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, s

News

New research from BenovelentAI supports use of Lilly's Olumi...

AI and machine learning drug development firm BenevolentAI has highlighted further data supporting its hypothesis that Eli Lilly’s Olumiant (baricitinib) could be a potential treatment for

News

BenevolentAI and Novartis sign AI R&D deal

The Artificial Intelligence (AI)-based drug development firm BenevolentAI has signed an agreement with Novartis to find potential new uses for oncology drugs already in its pipeline.

News

AZ researches kidney and lung drugs with BenevolentAI

AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal with the UK’s BenevolentAI to find new kidney and lung drugs.<